Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma Paolo A. Ascierto Commentary 31 December 2014 Pages: 271 - 274
Expression and function of Toll-like receptors in peripheral blood mononuclear cells from patients with ovarian cancer Xiaojie ZhangJuan XuShiyang Pan Original Article 07 November 2014 Pages: 275 - 286
Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease Madeeha ShamsBarbara OwczarczakSandra O. Gollnick Original Article Open access 11 November 2014 Pages: 287 - 297
Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm Larry A. HarshyneKirsten M. HooperD. Craig Hooper Original Article 14 November 2014 Pages: 299 - 309
Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1 Luara Isabela dos SantosBruno Galvão-FilhoRicardo Tostes Gazzinelli Original Article 18 November 2014 Pages: 311 - 323
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors Eugene M. CozzaTimothy K. CooperTodd D. Schell Original Article 19 November 2014 Pages: 325 - 336
Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients Johannes LandskronØystein HellandKjetil Taskén Original Article 22 November 2014 Pages: 337 - 347
Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma Anne Helene KøstnerMai-Britt Bjørklund EllegaardHenrik Schmidt Original Article 02 December 2014 Pages: 349 - 355
Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer Eva-Maria SurmannAnita Y. VoigtMatthias Kloor Original Article 02 December 2014 Pages: 357 - 366
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) Dan P. ZandbergSandra RollinsMartin J. Edelman Original Article 24 December 2014 Pages: 367 - 379
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases Sofie WilgenhofJurgen CorthalsBart Neyns Original Article 30 December 2014 Pages: 381 - 388
Tumor-induced CD14+HLA-DR−/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients Zhitao WangLulu ZhangZhimin Zhai Original Article 30 December 2014 Pages: 389 - 399